About Day One Biopharmaceuticals, Inc.
https://dayonebio.comDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
CEO
Jeremy Bender
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
Wedbush
Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:10.1M
Value:$108.35M
BLACKROCK, INC.
Shares:9M
Value:$96.59M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:6.43M
Value:$69M
Summary
Showing Top 3 of 191
About Day One Biopharmaceuticals, Inc.
https://dayonebio.comDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $39.8M ▲ | $59.57M ▼ | $-19.73M ▲ | -49.57% ▲ | $-0.19 ▲ | $-18.79M ▲ |
| Q2-2025 | $33.91M ▲ | $65.12M ▼ | $-30.32M ▲ | -89.42% ▲ | $-0.29 ▲ | $-29.36M ▲ |
| Q1-2025 | $30.76M ▲ | $68.94M ▼ | $-36M ▲ | -117.02% ▲ | $-0.35 ▲ | $-35.1M ▲ |
| Q4-2024 | $29.21M ▼ | $91.56M ▲ | $-65.71M ▼ | -224.99% ▼ | $-0.7 ▼ | $-58.48M ▼ |
| Q3-2024 | $93.76M | $62.53M | $37.04M | 39.5% | $0.38 | $36.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $451.58M ▼ | $513.78M ▼ | $62.91M ▲ | $450.87M ▼ |
| Q2-2025 | $453.1M ▼ | $519.04M ▼ | $58.2M ▲ | $460.83M ▼ |
| Q1-2025 | $473.02M ▼ | $534.36M ▼ | $54.84M ▼ | $479.51M ▼ |
| Q4-2024 | $531.72M ▼ | $582.79M ▼ | $80.04M ▲ | $502.75M ▼ |
| Q3-2024 | $558.38M | $600.81M | $45.34M | $555.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.73M ▲ | $-5.8M ▲ | $13.46M ▼ | $0 ▼ | $7.66M ▲ | $-5.8M ▲ |
| Q2-2025 | $-30.32M ▲ | $-24.81M ▲ | $26.32M ▲ | $748K ▲ | $2.26M ▲ | $-21.31M ▲ |
| Q1-2025 | $-36M ▲ | $-59M ▼ | $-32.61M ▲ | $0 ▼ | $-91.61M ▲ | $-62.81M ▼ |
| Q4-2024 | $-65.71M ▼ | $-30.01M ▼ | $-269.64M ▼ | $1.85M ▼ | $-297.8M ▼ | $-31.43M ▼ |
| Q3-2024 | $37.04M | $50.75M | $-67.7M | $200.09M | $183.15M | $-4.97M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ |
CEO
Jeremy Bender
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
Wedbush
Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:10.1M
Value:$108.35M
BLACKROCK, INC.
Shares:9M
Value:$96.59M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:6.43M
Value:$69M
Summary
Showing Top 3 of 191